Clinical Partners has raised new debt facilities
December 2025 — Clinical Partners Ltd. has successfully restructured and upsized its debt facilities to better reflect the scale of the business. The company increased its original US$9.4 million facility, comprising a US$3.4 million term loan and a US$6 million revolving credit facility (RCF), to a US$27 million RCF.
The new facility was secured on improved pricing and with enhanced documentation flexibility, providing additional headroom to support the company’s long-term strategy, including organic and acquisitive growth, as well as indirectly supporting a dividend to shareholders.
Clinical Partners is a leading provider of mental health services, working both privately and with the National Health Service (NHS) to help people of all ages achieve improved mental health outcomes. Through in-person and remote appointments, the company connects thousands of patients with senior clinicians across a broad range of mental health conditions, including autism, attention deficit hyperactivity disorder (ADHD), anxiety and depression.
Our role in the transaction
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised Clinical Partners in raising new debt facilities. The team supported the company throughout the process, helping to secure a structure aligned with its growth ambitions and long-term strategic objectives.
Falar com a equipa da transação
Transações relacionadas
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Saber maisRöntgeninstitut Aarau has been acquired by Evidia
The owners of Röntgeninstitut Aarau have sold the business to Evidia Group as part of their succession planning. The former owners will remain involved in the institute and support its future development alongside Evidia.
Saber maisLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Saber mais